PFS | OS | |||
---|---|---|---|---|
HR (CI95) | P | HR (CI95) | P | |
Age | 1.057 (0.984–1.135) | 0.130 | 1.049 (0.981–1.121) | 0.161 |
IPI | 1.433 (0.365–5.620) | 0.606 | 2.256 (0.580–8.767) | 0.240 |
Rituximab induction | 0.065 (0.011–0.367) | 0.002 | 0.192 (0.041–0.890) | 0.035 |
Upfront HD/ABSCT | 0.318 (0.065–1.562) | 0.158 | 0.498 (0.095–2.617) | 0.410 |
Remission post first line therapy (non-CR versus CR) | 0.106 (0.021–0.532) | 0.006 | 0.156 (0.032–0.748) | 0.020 |
Rituximab maintenance | 0.444 (0.046–4.264) | 0.482 | 0.360 (0.039–3.356) | 0.370 |